Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Eptifibatide API Manufacturers & Suppliers
15 verified results
Commercial-scale Suppliers
Employees: 250+
All certificates
Employees: 1000+
All certificates
Employees: 50+
All certificates
Employees: 1500+
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Eptifibatide | CAS No: 188627-80-7 | GMP-certified suppliers
A medication that supports treatment of acute coronary syndrome and myocardial infarction, helping reduce cardiac event risk for patients in critical care settings.
Therapeutic categories
Primary indications
- For treatment of myocardial infarction and acute coronary syndrome
Product Snapshot
- Eptifibatide is an injectable peptide supplied as an intravenous solution for parenteral use
- It is used in products targeting acute coronary syndrome and myocardial infarction pathways
- It is approved in major markets including the US, EU, and Canada, with some investigational evaluations ongoing
Clinical Overview
Pharmacologically, eptifibatide acts as a selective, reversible antagonist of the platelet glycoprotein IIb/IIIa receptor. This receptor is the final common pathway for platelet aggregation, mediating fibrinogen and von Willebrand factor binding during thrombus formation. By preventing ligand attachment, the drug inhibits platelet cross‑linking in a concentration‑dependent manner. The onset of pharmacodynamic effect is rapid after intravenous administration, with prompt reduction in platelet aggregation measurable shortly after therapeutic dosing.
Absorption is not relevant due to its parenteral use. Distribution is primarily within the plasma compartment, consistent with its peptide nature. Metabolism occurs through peptide hydrolysis to inactive fragments, and renal elimination contributes to systemic clearance. Exposure increases in renal impairment, and dose adjustments are typically required to mitigate bleeding risk. The terminal half‑life is short, supporting continuous infusion in clinical settings where sustained receptor blockade is needed.
Safety considerations focus on bleeding risk, which increases with concomitant anticoagulants, invasive procedures, and impaired renal function. Thrombocytopenia has been reported but is generally reversible upon discontinuation. There is no known intrinsic hepatotoxicity, and drug–drug interactions are primarily pharmacodynamic.
Eptifibatide is supplied in multiple regions under established parenteral brands for hospital use in interventional cardiology. For API procurement, sourcing teams should verify peptide integrity, stereochemistry, and impurity profiles, with particular attention to cyclic peptide stability and adherence to pharmacopeial or regionally recognized quality specifications.
Identification & chemistry
| Generic name | Eptifibatide |
|---|---|
| Molecule type | Biotech |
| CAS | 188627-80-7 |
| UNII | NA8320J834 |
| DrugBank ID | DB00063 |
Pharmacology
| Summary | Eptifibatide is an antiplatelet agent that reversibly blocks the platelet glycoprotein IIb/IIIa receptor, preventing fibrinogen and von Willebrand factor from mediating platelet aggregation. Its activity produces concentration‑dependent inhibition of platelet crosslinking central to thrombus formation in acute coronary events. Primary molecular interactions involve integrin beta‑3, with additional binding reported at N‑type calcium channels. |
|---|---|
| Mechanism of action | Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner. |
| Pharmacodynamics | Eptifibatide is an anti-coagulant that selectively and reversibly blocks the platelet glycoprotein IIb/IIIa receptor. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Integrin beta-3 | Humans | |
| Voltage-dependent N-type calcium channel | Humans | antagonist |
ADME / PK
| Half-life | Approximately 2.5 hours |
|---|---|
| Protein binding | Approximately 25% |
| Metabolism | No major metabolites have been detected in human plasma. Deamidated eptifibatide and other, more polar metabolites have been detected in urine. |
| Clearance | * 55 mL/kg/h [patients with coronary artery disease] |
Formulation & handling
- Eptifibatide is a biotech cyclic heptapeptide supplied as ready‑to‑use IV solutions, requiring parenteral‑grade handling and aseptic technique.
- As a peptide, it is used only by intravenous infusion and requires protection from excessive agitation to avoid foaming or adsorption.
- Formulation and storage should account for its antiplatelet mechanism, with awareness that co‑administration with anticoagulant‑like supplements may increase bleeding risk.
Regulatory status
| Lifecycle | Key patents for the API expired in the US between 2014 and 2015 and in Canada in 2013, indicating the product is well past loss of exclusivity. With availability across the US, EU, and Canada, the market is mature and likely characterized by established generic competition. |
|---|
| Markets | US, EU, Canada |
|---|
Supply Chain
| Supply chain summary | Eptifibatide was originally developed by a single originator, with manufacturing and packaging now carried out by multiple firms that support both branded and post‑patent supply. The product has established markets in the US, EU, and Canada, indicating broad global availability. Core patents expired between 2013 and 2015, suggesting that generic competition is already possible and may be present in the supply chain. |
|---|
Safety
| Toxicity | Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis) |
|---|
- Non‑clinical studies showed no lethality in rats, rabbits, or monkeys at 45 mg/kg via 90‑minute IV infusion, indicating a relatively wide acute exposure margin in tested species
- High-dose exposure in animals (2–5× human maximum daily dose on a mg/m² basis) supports classification as a peptide agent with low acute systemic toxicity under controlled laboratory conditions
- Standard precautions for handling injectable antiplatelet peptides apply due to potential for pharmacologic activity related to platelet aggregation inhibition
Eptifibatide is a type of Glycoprotein IIb/IIIa receptor antagonists
Glycoprotein IIb/IIIa receptor antagonists belong to a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the field of medicine. These antagonists specifically target and inhibit the activity of the glycoprotein IIb/IIIa receptors found on platelets.
The glycoprotein IIb/IIIa receptors play a crucial role in platelet aggregation, which is an essential step in the formation of blood clots. By blocking these receptors, glycoprotein IIb/IIIa receptor antagonists prevent platelets from binding to each other and forming clots, thereby inhibiting thrombus formation.
These pharmaceutical compounds have shown great potential in the treatment and prevention of conditions related to unwanted blood clotting, such as acute coronary syndromes and percutaneous coronary interventions. They are commonly used during angioplasty and stent placement procedures to reduce the risk of clot formation and subsequent complications.
Glycoprotein IIb/IIIa receptor antagonists are typically administered intravenously and have a relatively short duration of action. Common examples include abciximab, eptifibatide, and tirofiban. These agents are carefully monitored and controlled due to their potent antiplatelet effects.
It is important to note that the use of glycoprotein IIb/IIIa receptor antagonists requires close medical supervision, as they can increase the risk of bleeding. Therefore, healthcare professionals must carefully weigh the benefits and risks when considering the administration of these pharmaceutical APIs.
Eptifibatide (Glycoprotein IIb/IIIa receptor antagonists), classified under Anticoagulants
Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.
There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.
Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.
While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.
In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.
Eptifibatide API manufacturers & distributors
Compare qualified Eptifibatide API suppliers worldwide. We currently have 15 companies offering Eptifibatide API, with manufacturing taking place in 5 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| ALP PHARM | Producer | China | China | CoA, USDMF | 33 products |
| AMBIOPHARM | Producer | United States | Unknown | CoA, USDMF | 10 products |
| Chemi S.p.A. | Producer | Italy | Italy | CoA, GMP, USDMF | 18 products |
| Chengdu Shengnuo Biopharm... | Producer | China | China | BSE/TSE, CoA, GMP, MSDS, USDMF, WC | 33 products |
| Corden Pharma | Producer | Germany | Belgium | CoA, GMP, USDMF | 45 products |
| Flavine | Distributor | Germany | Unknown | CoA | 83 products |
| Hainan Shuangcheng | Producer | China | China | CoA, USDMF | 11 products |
| Hangzhou Thinheal Pharma-... | Producer | China | China | BSE/TSE, CoA, GMP, MSDS | 17 products |
| Hybio Pharmaceutical | Producer | China | China | CoA, USDMF | 8 products |
| Hybio Pharmaceutical Co L... | Producer | China | China | BSE/TSE, CoA, GMP, MSDS, USDMF, WC | 34 products |
| Polypeptide Labs | Producer | Sweden | Unknown | CoA, USDMF | 21 products |
| Sinoway industrial Co.,Lt... | Distributor | China | China | CoA, ISO9001, MSDS, USDMF | 762 products |
| Sun Pharma | Producer | India | India | CoA, GMP, USDMF, WC | 219 products |
| USV | Producer | India | India | CoA, FDA, GMP, USDMF, WC | 35 products |
| Wuxi Kaili | Producer | China | China | CoA, USDMF | 2 products |
When sending a request, specify which Eptifibatide API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Eptifibatide API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Eptifibatide API
Sourcing
What matters most when sourcing GMP-grade Eptifibatide?
Which documents are typically required when sourcing Eptifibatide API?
Which manufacturers are known to produce Eptifibatide API?
How can I request quotes for Eptifibatide API from GMP suppliers?
Is a GMP audit report available for Eptifibatide manufacturers?
How many suppliers offer Eptifibatide API on Pharmaoffer?
Which countries are known to manufacture Eptifibatide API?
Which certifications do suppliers of Eptifibatide usually hold?
Technical
What is Eptifibatide (CAS 188627-80-7) used for?
Which therapeutic class does Eptifibatide fall into?
What conditions is Eptifibatide mainly prescribed for?
How does Eptifibatide work?
What should someone know about the safety or toxicity profile of Eptifibatide?
What are important formulation and handling considerations for Eptifibatide as an API?
Is Eptifibatide a biotech?
Are there special stability concerns for oral Eptifibatide?
Regulatory
Where is Eptifibatide approved or in use globally?
What’s the regulatory and patent landscape for Eptifibatide right now?
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Eptifibatide procurement?
Is Eptifibatide included in the PRO Data Insights coverage?
Where can I access the API market report for Eptifibatide?
